Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 31, 2022
Grant Date -
Mar 22, 2018
app pub date -
Nov 10, 2017
filing date -
Aug 21, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2017 Application Filing Year
- A61K Class
- 21227 Applications Filed
- 12841 Patents Issued To-Date
- 60.50 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 2 Citation Count
- A61K Class
- 81.11 % this patent is cited more than
- 3 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Nov 30, 2025 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Nov 30, 2029 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Nov 30, 2033 |